The Federal Trade Commission announced on 19 August 2026 that it is seeking public comment on a proposed Enforcement Policy Statement regarding so-called “personalized pricing.” Personalised pricing refers to the practice of
More
The Centers for Medicare and Medicaid Services has increasingly positioned Medicare enrollment requirements as a key tool for maintaining program integrity across the healthcare system. Medicare enrollment has traditionally been viewed as
More
Biglaw firms are once again reaching deep into their pockets to attract high-performing associates, with signing bonuses making a notable comeback across the legal market. The resurgence reflects intense competition among major
More
The FTSE 100 opened firmly higher on Friday, recovering around 60% of Thursday’s decline as mining and financial stocks drove a broad blue-chip advance across London markets. London’s leading index gained 50.99
More
SentinelOne (NYSE: S) delivered a stronger-than-expected revenue performance in the second quarter of its 2026 fiscal year, yet the results failed to impress investors enough to lift the stock. The cybersecurity firm,
More
Dividend investing continues to attract significant interest from income-focused investors seeking reliable returns in an uncertain economic environment. Ultra-high-yield dividend stocks often carry a reputation for risk, but selective picks can offer
More
Aston Martin Lagonda (AML) is facing the prospect of being dropped from the FTSE 250 index as its much-anticipated turnaround continues to lose momentum. The British luxury carmaker has struggled to convince
More
Ronaldo has shared fresh photographs of his extraordinary car collection on Instagram, captioning the post simply “my toys” for his millions of followers. The Al-Nassr striker, aged 41, has previously admitted to
More
RayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in central Indiana operations and build a major new manufacturing facility. The company will establish an approximately 450,000-square-foot facility
More
Roivant Sciences (ROIV) and its partner Priovant Therapeutics have secured FDA approval for Lisraya, a first-in-class oral treatment for the rare autoimmune disease dermatomyositis. The U.S. Food and Drug Administration approved Lisraya,
More